Quick Links
About MyCOPDTeam
Powered By
Glycopyrronium Bromide - Does Anyone Else Use It?
I took part in a drugs trial last year - I was using a Spiriva inhaler on a daily basis, but was offered the chance to take part in trial of Glycopyrronium bromide and another drug - I found it helped and when the trial was finished I was offered the chance to go back to my original meds, or stay on this, which I did. I just wonder if any other members took part, or are finding this useful in their treatment of their COPD?
The trial ran for about 6 months last year @A MyCOPDTeam Member, and was run by Novartis - I had to fill out bi-monthly surveys and have spirometry tests, which did show a minor improvement over the period - I was advised before the end of the trial, which I was advised involved a sample of I believe 400, that the product I was using had been approved for use in Scotland - and I've been using it since with hardly any problems. This week however, has been particularly stressful, and I've now got a chest infection - the first since January 2015.
I am surprised they are still trialing what is called a SEEBRI inhaler....which is what you were on....Since that we had the ONBREZ and now the latest in the same Norvartis Family...ULTIBRO breezehaler...All 3 are 1 x day Combination Non Steroid inhalers...
COPY: About Seebri
Once-daily Seebri® Breezhaler® (EU)/ Seebri® Inhalation Capsules 50 mcg (Japan),
(NVA237, glycopyrronium bromide), is a novel inhaled long-acting muscarinic antagonist
(LAMA) indicated as a maintenance bronchodilator treatment to relieve symptoms in
adult patients with COPD. Seebri was first approved in the EU and Japan in SEPTEMBER
2012.... as a maintenance bronchodilator treatment for COPD; it has been approved in
over 50 countries including Canada and Australia and launched in Germany, the UK,
Japan and other major markets.
Glycopyrronium bromide was exclusively licensed to Novartis in April 2005
....................................................................................................................
Following approvals in Europe and Australia,in 2014, Ultibro has been approved as a long-term once-daily maintenance bronchodilator treatment of airflow
obstruction in patients with chronic obstructive pulmonary disease (COPD),
including chronic bronchitis and emphysema.
.....................................................................................................................
If you are in the US then the FDA are behind us in approving certain new meds...
@A MyCOPDTeam Member I would say that when they ran the trial I was asked to take part because my COPD was not too severe; you may find that your symptoms would not improve with it's use, but I would take all of Peter's info along to your health specialist/doctor and ask about it - it can't do any harm to ask, can it?
Post 3:
Here Is My Second Need In Life Style.
Hugs And Likes Are Great - Thanks -but A Distraction As My First Of Many Post To Concentrate On. Each Will Have Their Own Post.
Sign up for free!
Continue with Facebook
Sign up with your email
A MyCOPDT...
